Conditions: Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)
Keywords: Lung cancer; NSCLC
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 32
Healthy volunteers: no

Brief summary:
Primary objective: To assess the efficacy of various sequences of either a small molecule or an IMT (IMT-A) followed by a IMT-B (MEDI4736) .

Detailed description:
This is a multi-arm, multi-cohort, Phase IIa, open-label study of selected small molecules (gefitinib, AZD9291, or selumetinib + docetaxel) or 1st IMT (hereafter referred to as IMT-A; tremelimumab) followed by sequential switch to a 2nd IMT (hereafter referred to as IMT-B; MEDI4736) in locally advanced or metastatic NSCLC (Stage IIIB-IV). Patients will be enrolled concurrently into multiple cohorts.

Arms:
arm 1: Gefitinib once daily followed by MEDI4736 arm 2: AZD9291 once daily followed by MEDI4736 arm 3: Selumetinib twice daily + docetaxel, followed by MEDI4736 arm 4: Tremelimumab every 4 weeks followed by MEDI4736

Interventions: intervention 1: Gefitinib intervention 2: AZD9291 intervention 3: Selumetinib+Docetaxel intervention 4: Tremelimumab
Intervention descriptions: intervention 1: Gefitinib once daily followed by MEDI4736 intervention 2: AZD9291 once daily followed by MEDI4736 intervention 3: Selumetinib twice daily + docetaxel, followed by MEDI4736 intervention 4: Tremelimumab every 4 weeks followed by MEDI4736

Protocol document: